Skip to content
  • About Us
  • Pipeline
  • Publications
  • Careers
  • Investors
  • Careers
  • CLINICALTRIALS.GOV
  • The Crestone Study
  • Publications

    Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

    April 10, 2021April 7, 2021
    by Elevation Oncology
    Preclinical Diagnostics Genomic Testing Gene Fusions Data Research NRG1 fusion Partnership

    Virtual Poster Presentation

    Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

    Save this Presentation
    Download PDF
    Share
    Other Related Resources
    October 16, 2020February 22, 2021

    Posters & Oral Presentations

    CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More
    September 29, 2020February 22, 2021

    Posters & Oral Presentations

    CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More
    October 26, 2020March 1, 2021

    Posters & Oral Presentations

    The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements Read More
    January 15, 2021April 7, 2021

    Posters & Oral Presentations

    CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More
    March 29, 2021April 8, 2021

    Posters & Oral Presentations

    CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions Read More
    April 6, 2021April 6, 2021

    Manuscripts

    The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions Read More
    Publications
    • Our Focus
    • About Us
    • Careers
    • Contact
    • Investors
    • Terms
    • Privacy
    • ClinicalTrials.gov
    • The Crestone Study